%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
95 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-08T11:54:27Z
2024-03-28T02:37:29-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T02:37:29-07:00
application/pdf
Heather
200781.february
uuid:cdaaad4a-1dd1-11b2-0a00-890827bd3700
uuid:cdaaad4d-1dd1-11b2-0a00-5b0000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
105 0 obj
[109 0 R]
endobj
106 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.3347 Tw 10 0 0 10 54 536.1616 Tm
(occur in childhood cases, whether sicca symptoms are)Tj
-0.0182 Tw 0 -1.2 TD
(present or not)Tj
0 Tc 0 Tw 6.5 0 0 6.5 108.6131 527.4616 Tm
(3-5,7,8,15)Tj
-0.00011 Tc -0.0182 Tw 10 0 0 10 135.1508 524.1616 Tm
(. Some of the complications are serious,)Tj
0.0018 Tc 0.37309 Tw -8.1151 -1.2 Td
[(and need early recognition of the underlying SS. )17.9 (W)79.9 (e)]TJ
-0.00011 Tc 0.0659 Tw T*
(conclude that the detection of anti-)Tj
/T1_1 1 Tf
0 Tc 0 Tw [-0.4 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.0659 Tw [0.1 (-fodrin antibody could)]TJ
0.02499 Tw 0.0001 -1.2 Td
(be useful for early diagnosis of primary SS.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
-0.0069 Tw 8 0 0 8 54 454.1616 Tm
[(The authors thank Dr)54.8 (. R.T)73.9 (. Moon \(University of )17.8 (W)79.9 (ashington\) for providing)]TJ
0.02499 Tw 0 -1.25 TD
[(pGEX-JS-1 vector)54.8 (.)]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 54 422.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 412.1616 Tm
[(1.)-625.1 (T)69.9 (alal N. Clinical and pathological aspects of Sj\232gren\325)54.8 (s syndrome.)]TJ
1.375 -1.25 Td
[(Semin Clin Immunol 1993;6:1)36.8 (1-20.)]TJ
-1.375 -1.25 Td
[(2.)-625.1 (Chudwin DS, Daniels )17.7 (TE, )17.7 (W)79.9 (ara DW)91.7 (, et al. Spectrum of Sj\232gren)]TJ
1.375 -1.25 Td
(syndrome in children. J Pediatr 1981;98:213-7.)Tj
-1.375 -1.25 Td
[(3.)-625.1 (Anaya J-M, Ogawa N, )17.7 (T)69.9 (alal N. Sj\232gren\325)54.8 (s syndrome in childhood. )]TJ
1.375 -1.25 Td
[(J Rheumatol 1995;22:1)36.8 (152-8.)]TJ
-1.375 -1.25 Td
[(4.)-625.1 (Kobayashi I, Furuta H, )17.7 (T)69.9 (ame )54.8 (A, et al. Complications of childhood)]TJ
1.375 -1.25 Td
[(Sj\232gren\325)54.8 (s syndrome. Eur J Pediatr 1996;155:890-4.)]TJ
-1.375 -1.25 Td
[(5.)-625.1 (T)69.9 (omiita M, Saito K, Kohno )36.8 (Y)128.9 (, Shimojo N, Fujikawa S, Niimi H.)]TJ
1.375 -1.25 Td
[(The clinical features of Sj\232gren\325)54.8 (s syndrome in Japanese children.)]TJ
T*
(Acta Paediatr Jpn 1997;39:268-72.)Tj
-1.375 -1.25 Td
[(6.)-625.1 (Haneji N, Nakamura )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (akio K, et al. Identification of )]TJ
/T1_1 1 Tf
0 Tc 0 Tw 23.8245 0 Td
(\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin as a)]TJ
-22.4494 -1.25 Td
[(candidate autoantigen in primary Sj\232gren\325)54.8 (s syndrome. Science)]TJ
0 Tc 0 Tw T*
(1997;276;604-7.)Tj
-0.00011 Tc 0.02499 Tw -1.375 -1.25 Td
[(7.)-625.1 (Kobayashi I, Ishikawa N, )17.7 (T)69.9 (aneichi K, Konno M. Four cases of)]TJ
1.375 -1.25 Td
[(Sj\232gren\325)54.8 (s syndrome in children [English abstract]. J Jpn Pediatr Soc)]TJ
0 Tc 0 Tw T*
(1989;93:2073-8.)Tj
-0.00011 Tc 0.02499 Tw 31.625 35.671 Td
[(8.)-625.1 (Kumon K, Satake )54.8 (A, Mizumoto M, Kobayashi I, Ishikawa N. )54.8 (A)-220.1 (case)]TJ
1.375 -1.25 Td
[(of sensory neuropathy associated with childhood Sj\232gren\325)54.8 (s)]TJ
T*
(syndrome. Eur J Pediatr 2000;159:630-1.)Tj
-1.375 -1.25 Td
[(9.)-625.1 (V)59.8 (itali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary)]TJ
1.375 -1.25 Td
[(criteria for the classification of Sj\232gren\325)54.8 (s syndrome. Results of a)]TJ
T*
(prospective concerted action supported by the European)Tj
T*
[(Community)64.9 (. )54.8 (Arthritis Rheum 1993;36:340-7.)]TJ
-1.875 -1.25 Td
[(10.)-625.1 (Moon R)59.7 (T)74 (, McMahon )54.8 (AP)110.8 (. Generation of diversity in nonerythroid)]TJ
1.875 -1.25 Td
(spectrins. Multiple polypeptides are predicted by sequence analysis)Tj
T*
(of cDNAs encompassing the coding region of human nonerythroid)Tj
T*
(alpha-spectrin. J Biol Chem 1990;265:4427-33.)Tj
-1.8381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-625.1 (W)79.9 (atanabe )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (suchida )17.7 (T)74 (, Kanda N, Mori K, Hayashi )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (amaki K.)]TJ
-0.0002 Tc 0 Tw 1.8381 -1.25 Td
(Anti-)Tj
/T1_1 1 Tf
0 Tc [-0.3 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin antibodies in Sj\232gren syndrome and lupus)]TJ
T*
[(erythematosus. )54.8 (Arch Dermatol 1999;135:535-9.)]TJ
-1.875 -1.25 Td
[(12.)-625.1 (Martin SJ, O\325Brien GA, Nishioka )17.7 (WN, et al. Proteolysis of fodrin)]TJ
1.875 -1.25 Td
(\(non-erythroid spectrin\) during apoptosis. J Biol Chem)Tj
0 Tc 0 Tw T*
(1995;270:6425-8.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(13.)-625.1 (Leroy JP)110.7 (, Pennec )36.8 (YL, Soulier C, Berhelot JM, Letoux G, )36.7 (Y)99.8 (ouinou P)110.7 (.)]TJ
1.875 -1.25 Td
[(Follow up study labial salivary gland lesions in primary Sj\232gren\325)54.8 (s)]TJ
0 Tc T*
[(syndrome. )54.9 (Ann Rheum Dis 1992;51:777-80.)]TJ
-1.875 -1.25 Td
[(14.)-625 (Jonsson R, Kroneld U, B\212ckman K, Magnusson B, )17.8 (T)70 (arkowski )54.9 (A.)]TJ
-0.00011 Tc 1.875 -1.25 Td
[(Progression of sialadenitis in Sj\232gren\325)54.8 (s syndrome. Br J Rheumatol)]TJ
0 Tc T*
(1993;32 578-81.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(15.)-625.1 (Ohtsuka )17.7 (T)74 (, Saito )36.8 (Y)128.9 (, Hasegawa M, et al. Central nervous system)]TJ
1.875 -1.25 Td
(disease in a child with primary Sj\232gren syndrome. J Pediatr)Tj
0 Tc 0 Tw T*
(1995;127:961-3.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 36.0898 Tm
[(Kobayashi, et al: )17.7 (Anti-)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 8 0 1.7005 8 127.8305 36.0898 Tm
(\002)Tj
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 132.8774 36.0898 Tm
(-fodrin autoantibody in SS)Tj
0 Tc 0 Tw 51.6403 -0.0444 Td
(365)Tj
ET
0 0 0 0 k
/GS0 gs
102.25 59.75 407.5 -10.83 re
f*
0.5 w
102.25 59.75 407.5 -10.83 re
S
q
0.0444 TL /Fm0 Do
Q
q
0.0444 TL /Fm1 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_3 1 Tf
-0.00011 Tc 0.0192 Tw 8 0 0 8 124 587.4004 Tm
[(Figur)36.8 (e 1.)]TJ
/T1_0 1 Tf
0.0191 Tw 3.9729 0 Td
(Immunoblot analysis of anti-)Tj
/T1_1 1 Tf
0 Tc 0 Tw [-0.4 (\002)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.0191 Tw [0.1 (-fodrin antibody using fusion protein GST)91.7 (-JS-1. Sera from Patients 4, 5,)]TJ
0.02499 Tw -3.9729 -1.25 Td
[(and 9 were obtained one year before anti-SSA)-220.2 (and SSB antibodies became positive.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_4 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
21 0 obj
<>stream
8;Z\7MfHWW%+RPpLOIg1IC)aTUE9]!Oh"f%77eKEOJaJr,SS+5g\uf@8h>KC+KWLG
4Zl,;lZ_9aNr.\]nP7+^L%%7@F,]6C9gB`&'C6B2MKt`UmYMs^G\+\[@9uNnjnYfN
M&CtS32%A;"Y'7F&Ba!R+QX=M50#NlNeSR#neFLmnL@n.8
&=kpE&k)d?"b&5%S5-ipnDDN75DcBRrd?
oO27<9?ROW8X7RIMc;!fL^RP`)luAi?D_A#8X"a*78IDQS.7Z4-BeXI^0>AQgFR-(
H$tcFkBD]\oeVIlW-$/eCu/=ibn-q'kS)AZ!lr^95D]);m_($b/-T`:Wlo;L*nIWP
A[.M#-qb0d"H++DcNSPXn>0:;-(!)?o$:'b=P-+^eI>]ae^m8ZoX[e5*N0=
jbB3F8X'28Hta$`doSp&@beD/gU:tR[^?Pa[K`Rd-t`fG./X%j]s<%ln_)LoJKf!K~>
endstream
endobj
25 0 obj
[/Indexed/DeviceRGB 255 24 0 R]
endobj
24 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
11 0 obj
<>stream
H$A
0DO00f/RPfy): [6E6 m+唘'hr
aa*υY*? nL
endstream
endobj
16 0 obj
<>stream
H$A
0DO0w4 '{=@R?Xf3{ი^M2'b_
+_Gq:FOUxbGx#KAJ4+x1n
)Oo\z~ &
endstream
endobj
15 0 obj
<1.3<>>>
endobj
13 0 obj
<>/ProcSet[/PDF/ImageB]/XObject<>>>
endobj
12 0 obj
<>/Filter/CCITTFaxDecode/Height 263/ImageMask true/Length 1397/Subtype/Image/Type/XObject/Width 1447>>stream
Y]"ƃ
3*vJo2>Hh}>l$~ɱjᅮb?;Kӂg`BGQN.l}@fԈNO
BL e 'Gڦ*{by~0'*]aodp
l;__6:O6
c5dxv?]6a5&Sq"}[
MIaaT;#Gzi6l'A66a֓t~.}6'v]'V_m&l?.+M
}ma3Mokxpl7_~GoM5UL&i"l)oz_tCMl* 4?{a(a+9EYX!3$-}㵵t}n$I]LS"_ՅitU#L4!>+JY`b0MRʗ BhDG"++XIGXRQ<LYiA982uFGU<ވaGr^.
f2DzZAlK`
P)RbmKIPyk$9KL.,4as[)-R^6a-eaDs#< 5]+!;hh",ȄGPA;avRv
vT-'|(AOoge]^:iocSb#=WA:C*W GcL;+.CmIC>.k{y^G>0=FtcZ6@;O!6A}&I }k^6R
Ko$mMaRl*/åj^J@mÿT^
!I>.}oIPh:սPkv'aЎA:.,;_[ظq{i-\